VistaGen Therapeutics Stock Price Rises Above 50-Day Average

Analysts Weigh In on Whether It's Time to Sell

Mar. 21, 2026 at 8:18pm

Got story updates? Submit your updates here. ›

VistaGen Therapeutics, Inc. (NASDAQ:VTGN)'s stock price has risen above its 50-day moving average, prompting analysts to assess whether it's time for investors to sell the biopharmaceutical company's shares.

Why it matters

VistaGen Therapeutics is a clinical-stage company focused on developing treatments for central nervous system disorders. The movement of its stock price above the 50-day average is a potentially significant technical indicator that could influence investor sentiment and trading activity.

The details

VistaGen's stock price reached as high as $0.6489 on Thursday, surpassing its 50-day moving average of $0.60. The stock ultimately closed the day at $0.6423, with 499,129 shares traded. Analysts have provided mixed ratings on the stock, with one issuing a 'sell' recommendation and four others rating it as 'hold'.

  • VistaGen's stock price passed above its 50-day moving average during trading on Thursday, March 21, 2026.

The players

VistaGen Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders.

Weiss Ratings

A research firm that issued a 'sell (d-)' rating on VistaGen Therapeutics shares.

Maxim Group

An investment firm that reaffirmed a 'hold' rating on VistaGen Therapeutics shares.

Stifel Nicolaus

An investment bank that lowered its rating on VistaGen Therapeutics from 'buy' to 'hold' and set a $1.00 price target.

William Blair

A financial services firm that maintained a 'market perform' rating on VistaGen Therapeutics shares.

Jefferies Financial Group

An investment bank that reiterated a 'hold' rating and $0.90 price target on VistaGen Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The rise in VistaGen Therapeutics' stock price above its 50-day moving average is a technical indicator that could influence investor sentiment, but analysts remain divided on the company's prospects, with a mix of 'hold' and 'sell' ratings.